| Document |
Document Title |
|
WO/2005/012274A1 |
A process for the preparation of 11-(1-piperazinyl)dibenzo-[b, f ] [ 1, 4 ] thiazepine comprising reacting phenyl 2(phenylthio) phenylcarbamate with piperazine and cyclizing the obtained N-[ (2 -phenylthio) phenyl ] -1 -piperazinylcarb...
|
|
WO2004078735A9 |
The present invention relates to novel polymorphic forms of quetiapine fumarate, processes for their preparation and pharmaceutical compositions containing them.
|
|
WO/2004/080391A2 |
This invention relates to novel macrolides, to the preparation of novel macrolides, to the use of such novel macrolides for preventing, treating, or ameliorating various conditions, and to the use of such novel macrolides as antibacteria...
|
|
WO/2004/076430A1 |
Compounds of formula: (I) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia are described. Processes...
|
|
WO/2004/076431A1 |
Provided are a novel synthesis of quetiapine, quetiapine made by such process and its acid addition salts, and pharmaceutical composition comprising quetiapine so mad, or its acid addition salts.
|
|
WO/2004/073642A2 |
The present invention provides a combinatorial approach to a library of novel compounds having four diversity points. The compounds provide for the mapping of urotensin II and somatostatin 5 receptors by differential binding of said rece...
|
|
WO/2004/058734A1 |
The present invention comprises a simplified synthesis of (+)-diltiazem through IE-PdOsW wherein IE is ion-exchanger, catalyzed three-component coupling reaction and Fe3+-exchanged clay catalyzed ring opening of sulfite with 2-aminothiop...
|
|
WO/2004/056182A1 |
Use of compounds of formula (I): wherein X is S, O, S=O, SO2, NRa, or CRbRc;R1,R2 are halogen, OH, SH, NH2, CN, NO2, alkyl, alkoxy, alkylamino, dialkylamino, alkylthio, alkenyl, alkenyloxy, alkenylamino, alkenylthio, alkynyl, alkynyloxy,...
|
|
WO/2004/047722A2 |
Disclosed is a method of preparing 10H-dibenzo[b,f][1,4]thiazepin-11-one, including reacting dithiosalicylic acid with 1-chloro-2-nitrobenzene in a basic aqueous solution in the presence of absence of a reducing agent, to prepare 2-(2-ni...
|
|
WO/2004/031154A1 |
Compounds having the formula (I) pharmaceutical compositions containing them and their methods of use for the treatment of neurological disorders related to amyloid ß protein production and neurological disorders such as Alzheimer's dis...
|
|
WO/2004/020421A1 |
It is intended to provide drugs useful as preventives and remedies for hyperlipemia, etc., drugs useful as preventives and remedies for hepatopathy accompanying cholestasis (in particular, primary biliary cirrhosis, primary sclerosing ch...
|
|
WO/2004/009530A1 |
A process for the production of compounds represented by the general formula (3) and having high purity: (3) [wherein R1 is C1-6 alkyl or the like and R2 is hydrogen or the like, or R1 and R2 may be united to form C1-6 alkylene; and R3 a...
|
|
WO/2003/104257A2 |
This invention relates in general to certain substituted substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamides of formula (I) as defined herein which are protease inhibitors.
|
|
WO/2003/080065A1 |
The present invention relates to novel crystalline forms of quetiapine hemifumarate (I), denominated quetiapine hemifuramate form II and quetiapine hemifuramate form III. These novel crystalline forms of quetiapine hemifuramate have been...
|
|
WO/2003/031376A1 |
A solid phase synthetic method for making substituted 1,5-benzodiazepine-2-one or 1,5-benzothiazepine-2-one. The method is useful for synthesis of large numbers of compounds through automated parallel synthesis or combinatorial library g...
|
|
WO/2003/024941A1 |
Naphthalene compounds represented by the general formula (1) or pharmaceutically acceptable salts, hydrates or solvates thereof, which exhibit anti−HIV activity and are useful in the treatment of AIDS: (1) wherein each symbol is as def...
|
|
WO/2003/022286A1 |
The present invention relates to compounds of formula (I) wherein R?v¿, R?1¿, R?2¿, R?x¿, R?y¿, M, R?z¿, v, R?3¿, R?4¿, R?5¿ and R?6¿ are as defined within; pharmaceutically acceptable salts, solvates, solvates of such salts an...
|
|
WO/2003/022825A1 |
The present invention relates to compounds of formula (I): wherein variable groups are as defined within; pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport...
|
|
WO/2003/020710A1 |
The present invention relates to compounds of formula (I), wherein variable groups are as defined within; pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport...
|
|
WO/2003/018019A2 |
An agent comprising a compound of Formula (I-a) and the like, or a salt thereof, use of a compound of Formula (I-a) and the like, or a salt thereof for the manufacture of a medicament, or a method comprising administering a compound of F...
|
|
WO/2003/018009A1 |
The present invention relates to a combination comprising quetiapine or a pharmaceutically acceptable salt thereof and zolmitriptan or a pharmaceutically acceptable salt thereof, pharmaceutical compositions, processes for its preparation...
|
|
WO/2003/016294A1 |
The preparation of sultams is disclosed. In one embodiment (e.g. scheme (I)), an alkanesulfonyl halide is reacted with a haloalkylamine to obtain the corresponding N-(haloalkyl)alkanesulfonamide which is then cyclized in the presence of ...
|
|
WO/2003/016245A1 |
The present invention is directed to the separation of enantiomers of racemates of formula (I). The separation proceeds by applying deemed racemates to continuos enantioselective chromatography like SMB. The methods predominantly is perf...
|
|
WO/2003/002147A1 |
Preventives&sol remedies for organ functional disorders, preventives&sol remedies for organ dysfunction and preventives&sol remedies for obesity and sequels thereof which contain a compound having an effect of increasing ubiquinone, its ...
|
|
WO/2003/000670A1 |
The present invention provides novel compounds of Formula (I). The invention further relates to pharmaceutical compositions comprising compounds of Formula I and to methods of using compounds of Formula I to treat neuropsychiatric disord...
|
|
WO/2002/078625A2 |
The present invention provides therapeutic combinations and methods for treating or preventing a hypercholesterolemia-related or an inflammation -related condition in a subject in need of such treatment or prevention. One therapeutic com...
|
|
WO/2002/078626A2 |
The present invention provides therapeutic combinations and methods for treating or preventing a hypercholesterolemia-related or an inflammation-related condition in a subject in need of such treatment or prevention. One therapeutic comb...
|
|
WO1999063992A9 |
Novel multibinding compounds are disclosed. The compounds of this invention comprise 2 - 10 ligands covalently connected, each of the ligands being capable of binding to a ligand binding site in a Ca<++> channel, thereby modulating the b...
|
|
WO/2002/062346A1 |
This invention relates to a method of treating Substance Use such as Substance Abuse or Substance Dependence and in particular to the use of quetiapine in treating such disorders.
|
|
WO/2002/062324A2 |
Smooth muscle one modulators are applied topically to treat oesophageal motility disorders and gastro-oesophageal reflux disease. Topical application of the smooth muscle tone modulators reduces the risk of the unwanted side-effects obse...
|
|
WO/2002/060870A2 |
Methods and pharmaceutical compositions for the treatment of pain, preferably with lowered risk of induction of seizure in a patient. The compositions contain active compounds that are tricyclic $g(d) opioid receptor agonists of the gene...
|
|
WO/2002/053548A1 |
Compounds represented by the general formula [I]: [I] [wherein R?1¿ and R?2¿ are each hydrogen or C¿1-3? alkyl; R?3¿ is hydrogen or C¿1-6? alkyl(except n-butyl); R?4¿ is hydrogen, hydroxyl, or C¿1-3? alkyl; R?5¿ is a cyclic, satu...
|
|
WO/2002/051838A1 |
The invention relates to novel benzazepines and related heterocyclic derivatives (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes f...
|
|
WO/2002/051232A2 |
The invention relates to novel benzazepines and related heterocyclic derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for t...
|
|
WO/2002/049652A1 |
A method for treating dyskinesias associated with dopaminergic therapy is described using the atypical antipsychotic agent quetiapine. Also described is the co-administration of quetiapine and a dopaminergic agent for treating Parkinson'...
|
|
WO/2002/050051A1 |
The present invention relates to compounds of the formula (I): (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid tran...
|
|
WO/2002/046167A1 |
The present invention relates to compounds of the formula I wherein 1) Y is a bridge containing bridging heteroatoms and to their medicinal use; 2) As serotonin 1 (5-HT¿1?) receptor ligands, particularly in psychotherapeutic agents.
|
|
WO/2002/042258A1 |
N-protected-L-homocysteine disulfide of the formula (I) or an activated form thereof is reacted with (S)-2-amino-6,6-dimethoxyhexanoic acid, methyl ester to give the disulfide intermediate of the formula (II). The disulfide intermediate ...
|
|
WO/2002/024204A2 |
The invention provides compositions and methods for altering insulin secretion using an agent that inhibits calcium efflux via the mitochondrial calcium/ sodium antiporter (MCA). Methods of treatment are thereby provided, and are particu...
|
|
WO/2002/020019A1 |
A method of treating Attention Deficit Hyperactivity Disorder, Conduct Disorder and related disorders which comprises using the atypical antipychotic agent quetiapine.
|
|
WO/2002/010174A1 |
A process is described for the preparation of compounds with the following formula where the groups are as defined below; in particular, R¿1? is a substituted amine; said process includes essentially the reaction of pyrrolobenzothiazepi...
|
|
WO/2002/008211A2 |
Compounds, pharmaceutical compositions, and methods for the treatment of a hyperlipidemic condition in a subject. The compounds of the present invention are apical sodium co-dependent bile acid transport inhibitors and are 1,4-benzothiaz...
|
|
WO/2002/000626A1 |
Compounds according to general formulae (1 and 2), wherein G?1¿ is an azepine derivative and G?2¿ is a group according to general formulae (9 - 11) are new. Compounds according to the invention are vasopressin V¿2? receptor agonists. ...
|
|
WO/2001/079187A2 |
The present invention is directed to substituted 1,4-thiazepine and analogs thereof, represented by the general Formula (I): wherein the dashed lines, A?1¿, A?2¿, A?3¿, X?1¿ and R?1¿ are defined herein. The present invention also re...
|
|
WO/2001/077089A1 |
A compound having the general formula (I) and methods of using such compounds for the treatment of diseases and pharmaceutical composition comprising such compounds.
|
|
WO/2001/074348A2 |
Vasopeptidase inhibitors, especially omapatrilat, are useful in treating isolated systolic hypertension. The vasopeptidase inhibitor may be used in combination with other pharmaceutically active agents.
|
|
WO/2001/066533A1 |
The present invention relates to compounds of formula (I) wherein R?1¿ and R?2¿ are independently selected from C¿1-6?alkyl; one of R?4¿ and R?5¿ is a group of formula (IA): R?3¿, R?6¿, R?7¿, R?8¿, R?9¿, R?10¿ and R?11¿ and t...
|
|
WO/2001/060808A1 |
A compound of formula (I) in which R?1¿ is halo, lower alkoxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heterecyclic group or optionally substituted lower alkynyl, R?2¿ is amidated carboxy, R?...
|
|
WO/2001/055125A1 |
The invention refers to a novel process for the preparation of 11-[4-/2-(2-hydroxyethoxy)ethyl/-1-piperazinyl]dibenzo[b,f]-
1,4-thiazepine of the formula (I) known as quetiapine. According to the invention, a haloethylpiperazinylthiazepi...
|
|
WO/2001/055118A1 |
Benzene-fused heterocycle derivatives of the general formula (I); and nontoxic salts thereof (wherein each symbol is as defined in the description). The compounds of the general formula (I) exhibit inhibitory activities against cysteine ...
|
